Is Oncology Institute Stock a Good Investment?
Oncology Institute Investment Advice | TOI |
- Examine Oncology Institute's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Oncology Institute's leadership team and their track record. Good management can help Oncology Institute navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Oncology Institute's business and its evolving consumer preferences.
- Compare Oncology Institute's performance and market position to its competitors. Analyze how Oncology Institute is positioned in terms of product offerings, innovation, and market share.
- Check if Oncology Institute pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Oncology Institute's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Oncology Institute stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Oncology Institute is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Oncology Institute Stock
Researching Oncology Institute's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncology Institute has Price/Earnings (P/E) ratio of 190.67. The entity recorded a loss per share of 0.81. The firm had not issued any dividends in recent years.
To determine if Oncology Institute is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oncology Institute's research are outlined below:
| Oncology Institute generated a negative expected return over the last 90 days | |
| Oncology Institute has high historical volatility and very poor performance | |
| Oncology Institute has some characteristics of a very speculative penny stock | |
| Oncology Institute has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 324.24 M. Reported Net Loss for the year was (67.88 M) with profit before taxes, overhead, and interest of 52.09 M. | |
| Oncology Institute has about 64.21 M in cash with (36.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Disposition of 19526 shares by Hively Brad of Oncology Institute at 0.5753 subject to Rule 16b-3 |
Oncology Institute Quarterly Gross Profit |
|
Oncology Institute uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oncology Institute. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncology Institute's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Oncology Institute's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Oncology Institute's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2022-08-09 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2023-11-08 | 2023-09-30 | -0.13 | -0.19 | -0.06 | 46 | ||
2023-03-09 | 2022-12-31 | -0.18 | -0.25 | -0.07 | 38 | ||
2022-11-09 | 2022-09-30 | -0.18 | -0.25 | -0.07 | 38 | ||
2024-05-14 | 2024-03-31 | -0.12 | -0.22 | -0.1 | 83 | ||
2024-03-27 | 2023-12-31 | -0.11 | -0.21 | -0.1 | 90 | ||
2023-05-10 | 2023-03-31 | -0.17 | -0.33 | -0.16 | 94 |
Know Oncology Institute's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncology Institute is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncology Institute backward and forwards among themselves. Oncology Institute's institutional investor refers to the entity that pools money to purchase Oncology Institute's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-12-31 | 175.4 K | State Street Corporation | 2023-12-31 | 101.3 K | Squarepoint Ops Llc | 2023-12-31 | 96.9 K | Saba Capital Management, Lp | 2023-12-31 | 94.3 K | Renaissance Technologies Corp | 2023-12-31 | 89.3 K | Fielder Capital Group Llc | 2023-12-31 | 70.2 K | Northern Trust Corp | 2023-12-31 | 63.9 K | Diametric Capital, Lp | 2023-12-31 | 58.1 K | Bank Of New York Mellon Corp | 2023-12-31 | 48.7 K | Fmr Inc | 2023-12-31 | 4.8 M | Josh Arnold Investment Consultant, Llc | 2023-12-31 | 1.9 M |
Oncology Institute's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 39.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncology Institute's market, we take the total number of its shares issued and multiply it by Oncology Institute's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Oncology Institute's profitablity analysis
Oncology Institute's profitability indicators refer to fundamental financial ratios that showcase Oncology Institute's ability to generate income relative to its revenue or operating costs. If, let's say, Oncology Institute is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Oncology Institute's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Oncology Institute's profitability requires more research than a typical breakdown of Oncology Institute's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.33) | |
| Return On Capital Employed | (0.33) | (0.34) | |
| Return On Assets | (0.31) | (0.29) | |
| Return On Equity | (1.19) | (1.13) |
Determining Oncology Institute's profitability involves analyzing its financial statements and using various financial metrics to determine if Oncology Institute is a good buy. For example, gross profit margin measures Oncology Institute's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oncology Institute's profitability and make more informed investment decisions.
The data published in Oncology Institute's official financial statements usually reflect Oncology Institute's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Oncology Institute. For example, before you start analyzing numbers published by Oncology accountants, it's critical to develop an understanding of what Oncology Institute's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Oncology Institute's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncology Institute's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Oncology Institute's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncology Institute. Please utilize our Beneish M Score to check the likelihood of Oncology Institute's management manipulating its earnings.
Evaluate Oncology Institute's management efficiency
Oncology Institute has Return on Asset of (0.1768) % which means that on every $100 spent on assets, it lost $0.1768. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.0445) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The Oncology Institute's current Return On Tangible Assets is estimated to increase to -0.33. The current Return On Capital Employed is estimated to decrease to -0.34. As of now, Oncology Institute's Asset Turnover is decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.77 | 0.83 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 0.43 | 0.39 | |
| Enterprise Value Over EBITDA | (4.37) | (4.15) | |
| Price Book Value Ratio | 2.64 | 2.51 | |
| Enterprise Value Multiple | (4.37) | (4.15) | |
| Price Fair Value | 2.64 | 2.51 | |
| Enterprise Value | 236.8 M | 224.9 M |
The analysis of Oncology Institute's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Oncology Institute's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Oncology Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.829 |
Basic technical analysis of Oncology Stock
As of the 26th of May, Oncology Institute holds the Variance of 34.81, risk adjusted performance of (0.16), and Coefficient Of Variation of (343.03). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncology Institute, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate data for thirteen technical drivers for Oncology Institute, which can be compared to its competitors. Please check Oncology Institute coefficient of variation and maximum drawdown to decide if Oncology Institute is priced some-what accurately, providing market reflects its current price of 0.53 per share. As Oncology Institute is a penny stock we also suggest to check out its jensen alpha numbers.Oncology Institute's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncology Institute insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Oncology Institute's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Oncology Institute's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | 27.64 | |||
| Mean Deviation | 4.18 | |||
| Coefficient Of Variation | (343.03) | |||
| Standard Deviation | 5.9 | |||
| Variance | 34.81 | |||
| Information Ratio | (0.30) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.11) | |||
| Treynor Ratio | 27.63 | |||
| Maximum Drawdown | 38.31 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 7.27 | |||
| Skewness | (0.60) | |||
| Kurtosis | 2.82 |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | 27.64 | |||
| Mean Deviation | 4.18 | |||
| Coefficient Of Variation | (343.03) | |||
| Standard Deviation | 5.9 | |||
| Variance | 34.81 | |||
| Information Ratio | (0.30) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.11) | |||
| Treynor Ratio | 27.63 | |||
| Maximum Drawdown | 38.31 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 7.27 | |||
| Skewness | (0.60) | |||
| Kurtosis | 2.82 |
Consider Oncology Institute's intraday indicators
Oncology Institute intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oncology Institute stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Oncology Institute time-series forecasting models is one of many Oncology Institute's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncology Institute's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Oncology Stock media impact
Far too much social signal, news, headlines, and media speculation about Oncology Institute that are available to investors today. That information is available publicly through Oncology media outlets and privately through word of mouth or via Oncology internal channels. However, regardless of the origin, that massive amount of Oncology data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oncology Institute news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oncology Institute relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oncology Institute's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oncology Institute alpha.
Oncology Institute Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Oncology Institute can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oncology Institute without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Oncology Institute Corporate Management
Elected by the shareholders, the Oncology Institute's board of directors comprises two types of representatives: Oncology Institute inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncology. The board's role is to monitor Oncology Institute's management team and ensure that shareholders' interests are well served. Oncology Institute's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncology Institute's outside directors are responsible for providing unbiased perspectives on the board's policies.
| FACHE MD | Chief Officer | Profile | |
| Mark Esq | General Counsel | Profile | |
| Bradford Hively | CEO Director | Profile | |
| Rakesh MBA | Director Technology | Profile | |
| Laura Szitar | Chief Officer | Profile | |
| Richard Barasch | Executive Board | Profile | |
| Jeremy MBA | Chief Officer | Profile |
How to buy Oncology Stock?
To provide specific investment advice or recommendations on Oncology Institute stock, we recommend investors consider the following general factors when evaluating Oncology Institute. This will help you to make an informed decision on whether to include Oncology Institute in one of your diversified portfolios:- Examine Oncology Institute's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Oncology Institute's leadership team and their track record. Good management can help Oncology Institute navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Oncology Institute's business and its evolving consumer preferences.
- Compare Oncology Institute's performance and market position to its competitors. Analyze how Oncology Institute is positioned in terms of product offerings, innovation, and market share.
- Check if Oncology Institute pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Oncology Institute's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Oncology Institute stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Oncology Institute is a good investment.
Already Invested in Oncology Institute?
The danger of trading Oncology Institute is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Oncology Institute is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Oncology Institute. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Oncology Institute is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Oncology Institute's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share 4.635 | Quarterly Revenue Growth 0.242 | Return On Assets (0.18) | Return On Equity (1.04) |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Oncology Institute's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.